Is CYP2C19 genotype-guided de-escalation feasible and efficient in an all-comers ACS population?
Point-of-care CYP2C19 genotyping is a feasible and efficient strategy for guiding rapid de-escalation of antiplatelet therapy from ticagrelor to clopidogrel in patients with acute coronary syndrome.
CYP2C19 genotype-guided-de-escalation in an all-comers ACS population is feasible. POC genotyping leads to shorter turnaround times and quicker de-escalation. Time to de-escalation from ticagrelor to clopidogrel in noncarriers was short, with high physician adherence to genotype results.
Azzahhafi et al. (Sun,) studied this question.